What changed in this filing

/stocks — the workspaceLOADING

Item 1. Legal Proceedings

2026-02-06 compared with 2025-11-10 · 32 added, 31 removed, 17 unchanged (79% of the section changed)

10 unchanged sentences

3:24-cv-00035,was filed in the U.S.

District Court for

the District of Nevada, naming the Company and certain of its officers as defendants.

On February 22, 2024, a second, related putative

securities class action was filed in the same court asserting similar claims against the same defendants, captioned Way v.

District Court for the

District of Nevada, naming the Company and certain of its officers as defendants.

On February 22, 2024, a second, related putative securities

class action was filed in the same court asserting similar claims against the same defendants, captioned Way v.

2:24-cv-00361.

On April 15, 2024, the court consolidated these two actions under the caption In re BioVie Inc.

Litigation , No.

3:24-cv-00035, appointed the lead plaintiff, and approved selection of the lead counsel.

On June 21, 2024, the lead

plaintiff filed an amended complaint, alleging that the defendants made material misrepresentations and/or omissions of material fact

relating to the Company’s business, operations, compliance, and prospects, including information related to the NM101 Phase 3 study

and trial of bezisterim (NE3107) in mild to moderate probable AD, in violation of Sections

10(b) and 20(a) of the Exchange Act, and Rule 10b-5 promulgated thereunder.

The class action is on behalf of purchasers

of the Company’s securities during the period from December 7, 2022 through November 28, 2023, and seeks unspecified monetary damages

on behalf of the putative class and an award of costs and expenses, including attorney’s fees.

The defendants filed a motion to

dismiss the amended complaint on August 21, 2024, and that motion was fully briefed as of December 5, 2024.

On March 27, 2025, the court

denied the defendants’ motion to dismiss, and the parties are now engaged in fact discovery .

Three shareholder derivative lawsuits piggy-backing

on the securities class action were filed in the United States District Court for the District of Nevada, allegedly on behalf of the Company,

by three putative stockholders:

Securities Litigation ,

3:24-cv-00035 (the “Securities Class Action”), appointed the lead plaintiff, and approved selection of the lead counsel.

On June 21, 2024, the lead plaintiff filed an amended complaint, alleging that the defendants made material misrepresentations and/or

omissions of material fact relating to the Company’s business, operations, compliance, and prospects, including information related

to the NM101 Phase 3 study and trial of bezisterim (NE3107) in mild to moderate probable AD, in violation of Sections 10(b) and 20(a)

of the Exchange Act, and Rule 10b-5 promulgated thereunder.

The class action is on behalf of purchasers of the Company’s securities

during the period from December 7, 2022 through November 28, 2023, and seeks unspecified monetary damages on behalf of the putative class

and an award of costs and expenses, including attorney’s fees.

The defendants filed a motion to dismiss the amended complaint on

August 21, 2024, and denied on March 27, 2025, the court denied that motion.

The parties are now engaged in fact discovery.

Three shareholder derivative lawsuits piggy-backing on the Securities

Class Action were filed in the United States District Court for the District of Nevada, allegedly on behalf of the Company, by three putative

stockholders:

Andrew Hulm on December 30, 2024;

William Settel on April 28, 2025 and Cline Wilkerson on September 11,

2025, (collectively the “Related Derivative Lawsuits”).

Each Related Derivative Lawsuit names the same current and former

officers and directors as defendants and alleges essentially the same claims:

that the defendants breached their fiduciary duties by causing

or failing to prevent the securities violations alleged in the securities class action, and related claims for unjust enrichment, waste

of corporate assets, gross mismanagement, and abuse of control.

On September 29, 2025, at the request of the parties, the court consolidated

all three Related Derivative Lawsuits under the caption In re BioVie Inc .

William Settel on April 28, 2025 and Cline Wilkerson on September 11, 2025, (collectively

the “Related Derivative Lawsuits”).

Each Related Derivative Lawsuit names the same current and former officers and directors

as defendants and alleges essentially the same claims:

that the defendants breached their fiduciary duties by causing or failing to prevent

the securities violations alleged in the Securities Class Action, and related claims for unjust enrichment, waste of corporate assets,

gross mismanagement, and abuse of control.

On September 29, 2025, at the request of the parties, the court consolidated all three Related

Derivative Lawsuits under the caption In re BioVie Inc .

Derivative Litigation , Case No.

3:24-cv-0602-CSD.

3:24-cv-0602-CSD (the “Consolidated

Derivative Action”).

On January 27, 2026, at the request of the parties, the court stayed the Consolidated Derivative Action pending

resolution of a summary judgment motion by defendants in the Securities Class Action.

The Company believes that the claims are without

1 unchanged sentence

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Legal Proceedings